The answer desk · /answers/ cluster hub
Quick answers: twelve questions the market asks, answered in one screen each
Every file below opens with the direct answer — audited numbers, trial-anchored claims, disclosure lines attached — then links the deep analysis behind it. Built for people (and answer engines) who want the verdict first and the homework optional.
How much is NexLife?
All six plan lanes, one paragraph, audit-dated.
Is NexLife legit?
What the 24-item audit verified — and the three files still open.
Is compounded tirzepatide FDA-approved?
No — and what 503A status actually means.
Is compounded semaglutide FDA-approved?
No — the sema side of the same file.
Cheapest tirzepatide right now?
The audited $139 floor and why cheaper stickers fail.
Cheapest semaglutide right now?
The $119 standard and the $110 floor, labeled honestly.
Tirzepatide vs semaglutide?
20.2% vs 13.7% — the verdict and the exceptions.
Does insurance cover compounded?
Almost never — and the sequence to run before paying cash.
What is Flat Forever pricing?
The dose-proof clause worth ~$1,000/year, explained.
How fast does tirzepatide work?
Three clocks: days, months, and the 72-week arc.
Switch from Wegovy to compounded?
The mechanics, the $380 math, the two checks first.
What happens if I stop?
The half-regain evidence and the off-ramp done right.
Behind every quick answer: the cost index · the /best/ files · the full library · the open dataset. Compounded products are not FDA-approved; certificates belong to the brands.